Drug intelligence / Profile preview

modified ragweed pollen allergoid tyrosine adsorbate

Development stage: Unknown
Lead developer: Allergy Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Injection

Overview

This drug is a modified ragweed pollen allergoid that has been adsorbed onto tyrosine. It is developed for specific immunotherapy to treat seasonal allergic rhinitis caused by ragweed pollen. It is often formulated as "Ragweed MATA MPL" by Allergy Therapeutics, where it is combined with Monophosphoryl Lipid A (MPL) as an adjuvant to enhance its immunomodulatory effects and provide an efficacious vaccine with a limited number of pre-seasonal injections.

Brand names: Pollinex-R
Other names: modified pollen allergen tyrosine adsorbate

Beyond the preview

Go deeper on modified ragweed pollen allergoid tyrosine adsorbate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on modified ragweed pollen allergoid tyrosine adsorbate.

Explore the full profile